‘Pivotal’ Time for DLBCL Treatment Options

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

There are rapid advancements happening regarding treatment options for patients with diffuse large B-cell lymphoma (DLBCL). The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year. In this special issue of CURE, we are taking a close look at the new frontier of treatments for DLBCL.

“I do believe things are looking really good for patients with DLBCL,” Dr. Manali Kamdar, a clinical researcher in the field of blood cancers at the University of Colorado Anschutz Medical Campus, tells us.

Kamdar describes 2022 and 2023 as “pivotal in terms of having more medications approved for patients with large-cell lymphoma.”

Elsewhere in this issue, we speak with acclaimed singer-songwriter Mike Peters of Welsh rock band The Alarm. Peters wrote “Forwards,” his band’s latest album, while hospitalized for chronic lymphocytic leukemia.

“I thought (that) I might not come out of this place,” Peters said. “That plays on your mind quite a lot. You try to be positive about it all and suppress those darker thoughts, but they come out in the music. They just do. I think your optimism comes out stronger than your pessimism — for me it does, anyway.”

Also in this issue, we look at the history and potential benefits of minimal residual disease testing and offer insight from the Leukemia & Lymphoma Society regarding how patients can go about seeking the best treatment choices available and explore their options when it comes to enrolling in a clinical trial.

As always, we hope you find our stories inspirational and informative.

Thank you for reading.

MIKE HENNESSY JR.

President & CEO

MJH LIFE SCIENCES®

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.